Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1994 Nov;1(6):613–619. doi: 10.1128/cdli.1.6.613-619.1994

Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

H B Slade 1
PMCID: PMC368373  PMID: 8556510

Full text

PDF
613

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aledort L. M. Consequences of chronic hepatitis C: a review article for the hematologist. Am J Hematol. 1993 Sep;44(1):29–37. doi: 10.1002/ajh.2830440107. [DOI] [PubMed] [Google Scholar]
  2. Alter H. J., Purcell R. H., Shih J. W., Melpolder J. C., Houghton M., Choo Q. L., Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989 Nov 30;321(22):1494–1500. doi: 10.1056/NEJM198911303212202. [DOI] [PubMed] [Google Scholar]
  3. Alter M. J., Margolis H. S., Krawczynski K., Judson F. N., Mares A., Alexander W. J., Hu P. Y., Miller J. K., Gerber M. A., Sampliner R. E. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992 Dec 31;327(27):1899–1905. doi: 10.1056/NEJM199212313272702. [DOI] [PubMed] [Google Scholar]
  4. Antonelli A., Neri S., Gasperini L., Alberti B., Saracino A., Gambuzza C., Agostini S., Baschieri L. Monitoraggio delle prove di funzione epatica, dei markers dell'epatite A, B, C e degli anticorpi anti HIV nei pazienti trattati con immunoglobuline endovena (IVIG) per oftalmopatia basedowiana. Clin Ter. 1992 Sep;141(9 Pt 2):55–61. [PubMed] [Google Scholar]
  5. Batty I. Progress in standardization: 4 immunological reagents. Bull World Health Organ. 1976;54(2):123–128. [PMC free article] [PubMed] [Google Scholar]
  6. Biswas R. M., Nedjar S., Wilson L. T., Mitchell F. D., Snoy P. J., Finlayson J. S., Tankersley D. L. The effect on the safety of intravenous immunoglobulin of testing plasma for antibody to hepatitis C. Transfusion. 1994 Feb;34(2):100–104. doi: 10.1046/j.1537-2995.1994.34294143934.x. [DOI] [PubMed] [Google Scholar]
  7. Björkander J., Cunningham-Rundles C., Lundin P., Olsson R., Söderström R., Hanson L. A. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med. 1988 Jan;84(1):107–111. doi: 10.1016/0002-9343(88)90016-2. [DOI] [PubMed] [Google Scholar]
  8. Brettle R. P. Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet. 1985 Jan 5;1(8419):51–51. doi: 10.1016/s0140-6736(85)91001-3. [DOI] [PubMed] [Google Scholar]
  9. Cash J. D. Transmission of hepatitis C with pasteurised factor VIII. Lancet. 1992 Sep 12;340(8820):675–675. doi: 10.1016/0140-6736(92)92212-x. [DOI] [PubMed] [Google Scholar]
  10. Chambers L. A., Popovsky M. A. Decrease in reported posttransfusion hepatitis. Contributions of donor screening for alanine aminotransferase and antibodies to hepatitis B core antigen and changes in the general population. Arch Intern Med. 1991 Dec;151(12):2445–2448. doi: 10.1001/archinte.151.12.2445. [DOI] [PubMed] [Google Scholar]
  11. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  12. Conrad M. E. Prevention of post-transfusion hepatitis. Lancet. 1988 Jul 23;2(8604):217–217. doi: 10.1016/s0140-6736(88)92316-1. [DOI] [PubMed] [Google Scholar]
  13. Dammacco F., Sansonno D., Beardsley A., Gowans E. J. Failure to detect hepatitis C virus (HCV) genome by polymerase chain reaction in human anti-HCV-positive intravenous immunoglobulins. Clin Exp Immunol. 1993 May;92(2):205–210. doi: 10.1111/j.1365-2249.1993.tb03381.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dodd L. G., McBride J. H., Gitnick G. L., Howanitz P. J., Rodgerson D. O. Prevalence of non-A,non-B hepatitis/hepatitis C virus antibody in human immunoglobulins. Am J Clin Pathol. 1992 Jan;97(1):108–113. doi: 10.1093/ajcp/97.1.108. [DOI] [PubMed] [Google Scholar]
  15. Dodd R. Y. Hepatitis C virus, antibodies, and infectivity. Paradox, pragmatism, and policy. Am J Clin Pathol. 1992 Jan;97(1):4–6. doi: 10.1093/ajcp/97.1.4. [DOI] [PubMed] [Google Scholar]
  16. Donahue J. G., Muñoz A., Ness P. M., Brown D. E., Jr, Yawn D. H., McAllister H. A., Jr, Reitz B. A., Nelson K. E. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992 Aug 6;327(6):369–373. doi: 10.1056/NEJM199208063270601. [DOI] [PubMed] [Google Scholar]
  17. Finlayson J. S., Tankersley D. L. Anti-HCV screening and plasma fractionation: the case against. Lancet. 1990 May 26;335(8700):1274–1275. doi: 10.1016/0140-6736(90)91335-8. [DOI] [PubMed] [Google Scholar]
  18. Francis D. P., Hadler S. C., Prendergast T. J., Peterson E., Ginsberg M. M., Lookabaugh C., Holmes J. R., Maynard J. E. Occurrence of hepatitis A, B, and non-A/non-B in the United States. CDC sentinel county hepatitis study I. Am J Med. 1984 Jan;76(1):69–74. doi: 10.1016/0002-9343(84)90752-6. [DOI] [PubMed] [Google Scholar]
  19. Gretch D., Lee W., Corey L. Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory. J Clin Microbiol. 1992 Aug;30(8):2145–2149. doi: 10.1128/jcm.30.8.2145-2149.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hammarström L., Smith C. I. IgM production in hypogammaglobulinaemic patients during non-A, non-B hepatitis. Lancet. 1986 Mar 29;1(8483):743–743. doi: 10.1016/s0140-6736(86)91139-6. [DOI] [PubMed] [Google Scholar]
  21. Imbach P., Perret B. A., Babington R., Kaminski K., Morell A., Heiniger H. J. Safety of intravenous immunoglobulin preparations: a prospective multicenter study to exclude the risk of non-A, non-B hepatitis. Vox Sang. 1991;61(4):240–243. doi: 10.1111/j.1423-0410.1991.tb00953.x. [DOI] [PubMed] [Google Scholar]
  22. John T. J., Ninan G. T., Rajagopalan M. S., John F., Flewett T. H., Francis D. P., Zuckerman A. J. Epidemic hepatitis B caused by commercial human immunoglobulin. Lancet. 1979 May 19;1(8125):1074–1074. doi: 10.1016/s0140-6736(79)92964-7. [DOI] [PubMed] [Google Scholar]
  23. KISTLER P., NITSCHMANN H. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang. 1962 Jul-Aug;7:414–424. doi: 10.1111/j.1423-0410.1962.tb03274.x. [DOI] [PubMed] [Google Scholar]
  24. Kempf C., Jentsch P., Poirier B., Barré-Sinoussi F., Morgenthaler J. J., Morell A., Germann D. Virus inactivation during production of intravenous immunoglobulin. Transfusion. 1991 Jun;31(5):423–427. doi: 10.1046/j.1537-2995.1991.31591263197.x. [DOI] [PubMed] [Google Scholar]
  25. Koretz R. L., Abbey H., Coleman E., Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med. 1993 Jul 15;119(2):110–115. doi: 10.7326/0003-4819-119-2-199307150-00003. [DOI] [PubMed] [Google Scholar]
  26. Kumar A., Kulkarni R., Murray D. L., Gera R., Scott-Emuakpor A. B., Bosma K., Penner J. A. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol. 1993 Nov;41(3):205–209. doi: 10.1002/jmv.1890410307. [DOI] [PubMed] [Google Scholar]
  27. Lane R. S., Vallet L., Kavanagh M. L. Human immunoglobulin for clinical use. Lancet. 1983 Feb 12;1(8320):357–358. doi: 10.1016/s0140-6736(83)91662-8. [DOI] [PubMed] [Google Scholar]
  28. Leen C. L., Yap P. L., McClelland D. B., Atrah H. I., Crawford R. J., Mitchell R. Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet. 1985 Mar 9;1(8428):586–587. doi: 10.1016/s0140-6736(85)91249-8. [DOI] [PubMed] [Google Scholar]
  29. Lefrère J. J., Mariotti M., Trepo C., Li J. S., Lunel F., Frangeul L., Letourneur F., Laporte J. P., Jullien A. M. Testing for HCV-RNA in commercial intravenous immunoglobulins. Lancet. 1993 Mar 27;341(8848):834–835. doi: 10.1016/0140-6736(93)90615-n. [DOI] [PubMed] [Google Scholar]
  30. Lehner P. S., Webster A. D. Hepatitis C from immunoglobin infusions. BMJ. 1993 Jun 5;306(6891):1541–1542. doi: 10.1136/bmj.306.6891.1541-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lever A. M., Webster A. D., Brown D., Thomas H. C. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet. 1985 Mar 9;1(8428):587–587. doi: 10.1016/s0140-6736(85)91250-4. [DOI] [PubMed] [Google Scholar]
  32. Lever A. M., Webster A. D., Brown D., Thomas H. C. Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet. 1984 Nov 10;2(8411):1062–1064. doi: 10.1016/s0140-6736(84)91506-x. [DOI] [PubMed] [Google Scholar]
  33. Levi S., Foster C., Hodgson H. J., Ward K. N., So A., Garson J. A., Waxman J., Swirsky D. Chronic liver disease due to hepatitis C. BMJ. 1993 Apr 17;306(6884):1054–1056. doi: 10.1136/bmj.306.6884.1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lockner D., Bratt G., Lindborg A., Törnebohm E. Acute unidentified hepatitis in a hypogammaglobulinaemic patient on intravenous gammaglobulin successfully treated with interferon. Acta Med Scand. 1987;221(4):413–415. doi: 10.1111/j.0954-6820.1987.tb03365.x. [DOI] [PubMed] [Google Scholar]
  35. Louie R. E., Galloway C. J., Dumas M. L., Wong M. F., Mitra G. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals. 1994 Mar;22(1):13–19. doi: 10.1006/biol.1994.1003. [DOI] [PubMed] [Google Scholar]
  36. Menitove J. E. Rationale for surrogate testing to detect non-A, non-B hepatitis. Transfus Med Rev. 1988 Jun;2(2):65–75. doi: 10.1016/s0887-7963(88)70034-6. [DOI] [PubMed] [Google Scholar]
  37. Merican I., Sherlock S., McIntyre N., Dusheiko G. M. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med. 1993 Feb;86(2):119–125. [PubMed] [Google Scholar]
  38. Miller M. A., Orenstein P., Amihod B. Administration of immune serum globulin following exposure to hepatitis C virus. Clin Infect Dis. 1993 Feb;16(2):335–335. doi: 10.1093/clind/16.2.335. [DOI] [PubMed] [Google Scholar]
  39. Miller R. H., Purcell R. H. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci U S A. 1990 Mar;87(6):2057–2061. doi: 10.1073/pnas.87.6.2057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Morgado A. F., da Fonte J. G. An outbreak of hepatitis attributable to inoculation with contaminated gamma globulin. Bull Pan Am Health Organ. 1979;13(2):177–186. [PubMed] [Google Scholar]
  41. Nakamura S., Sato T. Letter: Acute hepatitis B after administration of gammaglobulin. Lancet. 1976 Feb 28;1(7957):487–487. doi: 10.1016/s0140-6736(76)91511-7. [DOI] [PubMed] [Google Scholar]
  42. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet. 1986 Feb 8;1(8476):322–323. [PubMed] [Google Scholar]
  43. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet. 1986 Feb 8;1(8476):322–323. [PubMed] [Google Scholar]
  44. Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet. 1985 Feb 16;1(8425):404–405. [PubMed] [Google Scholar]
  45. Nowak T., Gregersen J. P., Klockmann U., Cummins L. B., Hilfenhaus J. Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure. J Med Virol. 1992 Mar;36(3):209–216. doi: 10.1002/jmv.1890360311. [DOI] [PubMed] [Google Scholar]
  46. Pawlotsky J. M., Bouvier M., Deforges L., Duval J., Bierling P., Dhumeaux D. Chronic hepatitis C after high-dose intravenous immunoglobulin. Transfusion. 1994 Jan;34(1):86–87. doi: 10.1046/j.1537-2995.1994.34194098618.x. [DOI] [PubMed] [Google Scholar]
  47. Petrilli F. L., Crovari P., De Flora S. Hepatitis B in subjects treated with a drug containing immunoglobulins. J Infect Dis. 1977 Feb;135(2):252–258. doi: 10.1093/infdis/135.2.252. [DOI] [PubMed] [Google Scholar]
  48. Piazza M. Periodic gammaglobulin to prevent hepatitis C in at-risk sexual partners. Lancet. 1990 Sep 29;336(8718):823–824. doi: 10.1016/0140-6736(90)93298-4. [DOI] [PubMed] [Google Scholar]
  49. Prince A. M., Brotman B., Grady G. F., Kuhns W. J., Hazzi C., Levine R. W., Millian S. J. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet. 1974 Aug 3;2(7875):241–246. doi: 10.1016/s0140-6736(74)91412-3. [DOI] [PubMed] [Google Scholar]
  50. Prohaska W., Wolff C., Schlüter K., Köster-Eiserfunke W., Körner M. M., Kleesiek K. Immunoglobulin preparations from hepatitis C antibody-positive plasma donors: influence on diagnosis and risk of infection in heart transplant recipients. Clin Investig. 1992 Jul;70(7):573–578. doi: 10.1007/BF00184795. [DOI] [PubMed] [Google Scholar]
  51. Puoti M., Zonaro A., Ravaggi A., Marin M. G., Castelnuovo F., Cariani E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. Hepatology. 1992 Oct;16(4):877–881. doi: 10.1002/hep.1840160404. [DOI] [PubMed] [Google Scholar]
  52. Pérez-Trallero E., Cilla G., Iturriza M., Montes M., Saenz J. R. Commercial immunoglobulins and HCV. Lancet. 1990 Dec 22;336(8730):1590–1590. doi: 10.1016/0140-6736(90)93376-z. [DOI] [PubMed] [Google Scholar]
  53. Quinti I., Paganelli R., Scala E., Guerra E., Mezzaroma I., D'Offizi G. P., Aiuti F. Hepatitis C virus antibodies in gammaglobulin. Lancet. 1990 Dec 1;336(8727):1377–1377. doi: 10.1016/0140-6736(90)92927-a. [DOI] [PubMed] [Google Scholar]
  54. Reuter D., Polywka S., Iske L., Feucht H. H., Laufs R. Close correlation between hepatitis C virus serology and polymerase chain reaction in chronically infected patients. Infection. 1992 Nov-Dec;20(6):320–323. doi: 10.1007/BF01710675. [DOI] [PubMed] [Google Scholar]
  55. Rousell R. H., Budinger M. D., Pirofsky B., Schiff R. I. Prospective study on the hepatitis safety of intravenous immunoglobulin, pH 4.25. Vox Sang. 1991;60(2):65–68. doi: 10.1111/j.1423-0410.1991.tb00876.x. [DOI] [PubMed] [Google Scholar]
  56. Rousell R. H. Clinical safety of intravenous immune globulin and freedom from transmission of viral disease. J Hosp Infect. 1988 Aug;12 (Suppl 500):17–27. doi: 10.1016/0195-6701(88)90026-6. [DOI] [PubMed] [Google Scholar]
  57. Rousell R. H., Dobkin M. B., Budinger M. D., Louie R. E. Transmission of hepatitis after the administration of intravenous immunoglobulins. Am J Clin Pathol. 1993 May;99(5):649–649. doi: 10.1093/ajcp/99.5.649. [DOI] [PubMed] [Google Scholar]
  58. Rousell R. H., Good R. A., Pirofsky B., Schiff R. I. Non-A non-B hepatitis and the safety of intravenous immune globulin, pH 4.2: a retrospective survey. Preliminary communication. Vox Sang. 1988;54(1):6–13. doi: 10.1111/j.1423-0410.1988.tb01605.x. [DOI] [PubMed] [Google Scholar]
  59. Sakamoto N., Sato C., Haritani H., Maekawa S., Kurosaki M., Enomoto N., Hoshino Y., Tazawa J., Nishimura M., Marumo F. Detection of hepatitis C viral RNA in sporadic acute non-A, non-B hepatitis by polymerase chain reaction. Its usefulness for the early diagnosis of seronegative infection. J Hepatol. 1993 Jan;17(1):28–33. doi: 10.1016/s0168-8278(05)80517-3. [DOI] [PubMed] [Google Scholar]
  60. Schroeder D. D., Dumas M. L. A preparation of modified immune serum globulin (human) suitable for intravenous administration. Further characterization and comparison with pepsin-treated intravenous gamma globulin. Am J Med. 1984 Mar 30;76(3A):33–39. doi: 10.1016/0002-9343(84)90317-6. [DOI] [PubMed] [Google Scholar]
  61. Seeff L. B., Zimmerman H. J., Wright E. C., Finkelstein J. D., Garcia-Pont P., Greenlee H. B., Dietz A. A., Leevy C. M., Tamburro C. H., Schiff E. R. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology. 1977 Jan;72(1):111–121. [PubMed] [Google Scholar]
  62. Stevens C. E., Taylor P. E., Pindyck J., Choo Q. L., Bradley D. W., Kuo G., Houghton M. Epidemiology of hepatitis C virus. A preliminary study in volunteer blood donors. JAMA. 1990 Jan 5;263(1):49–53. [PubMed] [Google Scholar]
  63. Sugg U., Schneider W., Hoffmeister H. E., Huth C., Stephan W., Lissner R., Haase W. Hepatitis B immune globulin to prevent non-A, non-B post-transfusion hepatitis. Lancet. 1985 Feb 16;1(8425):405–406. doi: 10.1016/s0140-6736(85)91431-x. [DOI] [PubMed] [Google Scholar]
  64. Sánchez-Quijano A., Pineda J. A., Lissen E., Leal M., Díaz-Torres M. A., García De Pesquera F., Rivera F., Castro R., Muñoz J. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet. 1988 Jun 4;1(8597):1245–1249. doi: 10.1016/s0140-6736(88)92071-5. [DOI] [PubMed] [Google Scholar]
  65. Tabor E., Gerety R. J. Transmission of hepatitis B by immune serum globulin. Lancet. 1979 Dec 15;2(8155):1293–1293. doi: 10.1016/s0140-6736(79)92296-7. [DOI] [PubMed] [Google Scholar]
  66. Thomas D. L., Factor S. H., Kelen G. D., Washington A. S., Taylor E., Jr, Quinn T. C. Viral hepatitis in health care personnel at The Johns Hopkins Hospital. The seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection. Arch Intern Med. 1993 Jul 26;153(14):1705–1712. [PubMed] [Google Scholar]
  67. Tremolada F., Casarin C., Alberti A., Drago C., Tagger A., Ribero M. L., Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol. 1992 Nov;16(3):273–281. doi: 10.1016/s0168-8278(05)80657-9. [DOI] [PubMed] [Google Scholar]
  68. Troisi C. L., Hollinger F. B., Hoots W. K., Contant C., Gill J., Ragni M., Parmley R., Sexauer C., Gomperts E., Buchanan G. A multicenter study of viral hepatitis in a United States hemophilic population. Blood. 1993 Jan 15;81(2):412–418. [PubMed] [Google Scholar]
  69. Uemura Y., Yokoyama K., Nishida M., Suyama T. Immunoglobulin preparation: safe from virus transmission? Vox Sang. 1989;57(1):1–3. doi: 10.1111/j.1423-0410.1989.tb04974.x. [DOI] [PubMed] [Google Scholar]
  70. Watanabe J., Minegishi K., Mitsumori T., Ishifuji M., Oguchi T., Ueda M., Tokunaga E., Tanaka E., Kiyosawa K., Furuta S. Prevalence of anti-HCV antibody in blood donors in the Tokyo area. Vox Sang. 1990;59(2):86–88. doi: 10.1111/j.1423-0410.1990.tb05015.x. [DOI] [PubMed] [Google Scholar]
  71. Weiland O., Mattsson L., Glaumann H. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet. 1986 Apr 26;1(8487):976–977. doi: 10.1016/s0140-6736(86)91081-0. [DOI] [PubMed] [Google Scholar]
  72. Williams P. E., Yap P. L., Gillon J., Crawford R. J., Galea G., Cuthbertson B. Non-A, non-B hepatitis transmission by intravenous immunoglobulin. Lancet. 1988 Aug 27;2(8609):501–501. doi: 10.1016/s0140-6736(88)90138-9. [DOI] [PubMed] [Google Scholar]
  73. Williams P. E., Yap P. L., Gillon J., Crawford R. J., Urbaniak S. J., Galea G. Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin. Vox Sang. 1989;57(1):15–18. doi: 10.1111/j.1423-0410.1989.tb04977.x. [DOI] [PubMed] [Google Scholar]
  74. Yei S., Yu M. W., Tankersley D. L. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion. 1992 Nov-Dec;32(9):824–828. doi: 10.1046/j.1537-2995.1992.32993110753.x. [DOI] [PubMed] [Google Scholar]
  75. van der Poel C. L., Bresters D., Reesink H. W., Plaisier A. A., Schaasberg W., Leentvaar-Kuypers A., Choo Q. L., Quan S., Polito A., Houghton M. Early antihepatitis C virus response with second-generation C200/C22 ELISA. Vox Sang. 1992;62(4):208–212. doi: 10.1111/j.1423-0410.1992.tb01200.x. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES